BSEVeerhealth Care Ltd· Pharmaceuticals & BiotechnologyHighPositive
Announced Mon, 20 Apr, 2026 · 16:56 IST

Veerhealth Care wins biggest single order ₹6.16 cr from FMCG major

Order Above 5pct RevenueBusiness Updates View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.6%Reaction day
₹20.38
prior close
₹20.49
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.1%-0.5% vs market
Pharmaceuticals peers, median of 160sector+0.1%+0.5% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.2
10m
-0.9
15m
-0.9
30m
+1.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.6+1.1-0.5+0.1+0.5
Next day
-0.6+2.4-3.0+0.4-1.1
2d
-0.6+2.1-2.8+0.5-1.1
3d
-2.1+0.7-2.8-0.6-1.5
4d
+0.5+3.1-2.6+0.6-0.1
5d
+0.3+3.0-2.7+0.1+0.2
1w
-1.4+2.6-4.0+0.5-1.9
15d
+9.2+3.2+6.0+1.9+7.3
1m
+15.3+3.8+11.5+3.4+11.9
2m
+46.1+13.1+33.0+7.5+38.6
3m
+102.2+13.0+89.2+12.9+89.3
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Veerhealth Care received its biggest single order worth ₹6.16 cr from a leading Indian FMCG company for skincare/face care products, to be executed within ~35 days. The order is ~20% of expected FY26 revenues and ~85% of Q3 FY26 revenues. The buyer operates in personal and household care, part of a 125-year-old business group. Company targets ₹50-60 cr FY27 revenue with 7-10% PAT, and aims for ₹100 cr revenue in 18 months. Holds USFDA plant clearance.

Likely market impact

Large reputed order boosts near-term revenue visibility and may lift sentiment. Risk: heavy reliance on a single client and FMCG buyer concentration.